News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Arocell at Medica: A Successful Exhibition

Arocell recently participated as an exhibitor at the Medica trade fair, joining 5,800 other exhibitors from 72 countries. Medica showcases modern healthcare solutions for both outpatients and inpatients, making it a pivotal event in the medical industry. We engaged in...

read more